Cassava Sciences surges 148% on final phase 2 results

Cassava Sciences (NASDAQ:SAVA) held a conference this morning announcing promising Phase 2b trial results in treating patients with mild-moderate Alzheimer’s Disease. The company uses the drug Sumifilam to treat AD by reducing neurodegeneration and neuroinflammation. The results announced via conference call concluded that the data shows a promising increase in cognitive bio-markers within AD patients – an […]